Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 7/20 | 0.62 |
| ▸ | PPARA | Q07869 | 7/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3040459 | 0.89 | SCD (0.77) | SCDPPARAMAPTCHRM4PPARD | |
| SCHEMBL3044261 | 0.86 | SCD (0.68) | SCDPPARAMAPTCHRM4PPARD | |
| SCHEMBL3041775 | 0.83 | SCD (0.57) | SCDPPARAMAPTCHRM4PPARD | |
| SCHEMBL3041776 | 0.83 | SCD (0.57) | SCDPPARAMAPTCHRM4PPARD | |
| SCHEMBL3044135 | 0.83 | SCD (0.57) | SCDPPARAMAPTCHRM4PPARD | |
| SCHEMBL3035795 | 0.83 | SCD (0.65) | SCDPPARAMAPTPPARDLMNA | |
| SCHEMBL3047634 | 0.82 | SCD (0.75) | SCDPPARAMAPTPPARDLMNA | |
| SCHEMBL3045494 | 0.81 | SMN1; SMN2 (0.43) | SCDPPARAMAPT | |
| SCHEMBL3044560 | 0.80 | SCD (0.64) | SCDPPARAMAPTPPARDLMNA | |
| SCHEMBL15484693 | 0.80 | SCD (0.64) | SCDPPARAMAPTPPARDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086970-B1 | 2-(PYRAZIN-2-YL)-THIAZOLE AND 2-(1H PYRAZOL-3-YL)-THIAZOLE DERIVATIVES AS WELL AS RELATED COMPOUNDS AS STEAROYL-COA DESATURASE (SCD) INHIBITORS FOR THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND OTHER DISORDERS | NOVARTIS AG (CH) | 2014-02-26 | — | — | EP | disclosed |
| US-8314138-B2 | Pyrazole derivative as SCD1 inhibitors for the treatment of diabetes | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20100239520-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-2086970-A2 | 2-(PYRAZIN-2-YL)-THIAZOLE AND 2-(1H PYRAZOL-3-YL)-THIAZOLE DERIVATIVES AS WELL AS RELATED COMPOUNDS AS STEAROYL-COA DESATURASE (SCD) INHIBITORS FOR THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND OTHER DISORDERS | Novartis AG (CH) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008024390-A2 | 2- (PYRAZIN-2-YL) -THIAZOLE AND 2- (1H-PYRAZ0L-3-YL) -THIAZOLE DERIVATIVES AS WELL AS RELATED COMPOUNDS AS STEAROYL-COA DESATURASE (SCD) INHIBITORS FOR THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND OTHER DISORDERS | NOVARTIS AG (CH) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239520-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885PPARA 51/4885MAPT 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.